AGY Therapeutics, is dedicated to discovering and developing novel treatments for central nervous system (CNS) diseases, including stroke, Alzheimer's disease, depression, brain tumors and obesity. AGY Therapeutics is establishing a strong proprietary position for a large number of novel pharmaceutical agents, diagnostics and technologies. In its short history, the company has built a proprietary technology platform for functional gene discovery and for delineating specific mechanistic pathways underlying central nervous system diseases. AGY Therapeutics specializes in using animal models and tissue culture models to analyze the mechanistic pathways of disease progression. The company employs sequential molecular snapshots at multiple timepoints through the course of disease. This analysis results in understanding the location and expression of genes involved in the pathological process. Through this approach, AGY Therapeutics intends to identify optimal drug targets that can be used to develop therapeutic agents, as well as identify critical treatment time windows in which further central nervous system deterioration can be inhibited or tissue regeneration can occur.